(Q44076759)

29 November 2017

0 references

Editorial commentary: what constitutes appropriate treatment of post-Lyme disease symptoms and other pain and fatigue syndromes? (English)

1 reference

29 November 2017

0 references

1

Allen C Steere

1 reference

29 November 2017

Sheila L Arvikar

2

1 reference

PubMed ID

25852123

29 November 2017

language of work or name

English

0 references

publication date

6 April 2015

1 reference

Clinical Infectious Diseases

29 November 2017

1 reference

29 November 2017

60

1 reference

29 November 2017

12

1 reference

29 November 2017

1783-1785

1 reference

The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America

29 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

A Critical Appraisal of “Chronic Lyme Disease”

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Pathological pain and the neuroimmune interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

High-affinity glutamate transporters in chronic pain: an emerging therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Final report of the Lyme disease review panel of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Post-treatment lyme syndrome and central sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Unorthodox alternative therapies marketed to treat Lyme disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

Fibromyalgia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

A randomized trial of tai chi for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV187

21 January 2018

Identifiers

DOI

10.1093/CID/CIV187

1 reference

29 November 2017

1 reference

PubMed ID

25852123